Clinical Trials Browser

Phase 2/3 × Immune Checkpoint Inhibitors × Clear all

NCT05605613 2022-11-09

PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial

Phase 2/3 Unknown

NSCLC

NCT05322187 2022-04-11

sPLENTY-pc

Phase 2/3 Unknown

Gastrointestinal

Liver Neoplasms, Neoplasms, Hepatoblastoma